Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (140) and Ligand Pharmaceuticals (120). Figures as of 18 Nov 2026, 20:24 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.2
- Combined market value
- THB 172.32T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | THB 2.31T | THB 723.18 | 1.59% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 140 | THB 11.6T | THB 4,704.82 | 3.37% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | THB 202.7B | THB 10,135.70 | 1.58% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.5 | THB 338.8B | THB 2,241.36 | 5.25% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.1 | THB 1.67T | THB 1,431.92 | 1.07% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 73.0 | THB 537.5B | THB 8,374.03 | 2.44% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | THB 253.5B | THB 3,226.20 | 0.12% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.5 | THB 257.9B | THB 740.16 | 3.20% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.8 | THB 1.57T | THB 13,708.63 | 2.32% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.2 | THB 252.8B | THB 2,310.30 | 2.91% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.2 | THB 17.2T | THB 9,733.28 | 2.12% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 45.2 | THB 1.35T | THB 2,346.81 | 0.62% up | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 45.1 | THB 41.99T | THB 47,136.82 | 1.95% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.7 | THB 1.07T | THB 1,737.05 | 1.56% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.7 | THB 425B | THB 509.74 | 1.49% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.6 | THB 22.39T | THB 9,298.93 | 1.75% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.2 | THB 5.44T | THB 955.13 | 1.21% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.2 | THB 6.18T | THB 3,565.46 | 0.27% up | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.6 | THB 4.63T | THB 18,275.40 | 0.74% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | THB 9.96T | THB 5,271.27 | 2.46% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.8 | THB 280.6B | THB 4,299.34 | 1.55% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | THB 9.43T | THB 6,082.75 | 1.73% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.5 | THB 3.85T | THB 1,602.40 | 0.73% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.9 | THB 838.6B | THB 19,691.37 | 0.73% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | THB 3.33T | THB 32,148.91 | 1.16% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | THB 603.7B | THB 9,203.33 | 0.07% down | 28% up | ||
| 27 | GSKGSK · Health Care | 17.0 | THB 3.32T | THB 1,654.87 | 1.04% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.7 | THB 1.19T | THB 2,934.48 | 3.51% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.3 | THB 4.16T | THB 2,036.24 | 2.27% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | THB 195.3B | THB 286.96 | 2.09% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | THB 5.9T | THB 1,339.72 | 3.07% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | THB 679.9B | THB 5,076.51 | 4.48% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 5.0 | THB 154.4B | THB 1,410.02 | 1.24% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 33.9600 THB). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (140) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 20:24 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of THB 172.32T as of 18 Nov 2026, 20:24 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.